Vaccine manufacturers and ancillaries are anticipating a strong demand from the government for Covid-19 vaccines alone after the government announced its plans to procure ₹35,000 crore worth of jabs, an amount estimated to be enough to vaccinate roughly half of the country’s population.

Over the last 15-odd months, the surge in demand for medicines to treat Covid-19 has been intense and with life-and-death consequences for patients.But navigating this ebb and flow in demand are a bunch of rather low-profile companies.

Pharma-packaging firm based in Mumbai, Kaisha Packaging has successfully provided over 2 billion doses worth of flip-top aluminium seals used for packaging COVID-19 vaccines. The seal is used as a closure for injection vials during the vaccination drive and is as such an essential part of the vaccine package ensuring tamper-proof delivery.

With several countries joining the race for the Coronavirus vaccine, India has been getting several requests for the supply of ampoules, vials and syringes which play a critical role in administering the vaccine to the population on a mass level

India, the world’s biggest vaccine maker, is getting set for the massive global blitz to contain the coronavirus pandemic with its pharmaceutical industry and partners freeing up capacity and accelerating investments even without firm purchase ordersp>

India, the world’s biggest vaccine maker, is getting set for the massive global blitz to contain the coronavirus pandemic with its pharmaceutical industry and partners freeing up capacity and accelerating investments even without firm purchase orders.

The three-decade old partnership of Kairus Dadachanji and Shapoorji Pallonji Mistry has resulted in yet another milestone in India’s pharmaceutical landscape with the birth of ‘KAISHA LIFESCIENCES’. With multi-crore investment and a team of skilled pharma specialists committed to developing superior quality generic injectables and any other forms of medicine, KAISHA LIFESCIENCES is a privately-owned company